Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
Clinical trial NCT05532124 · COMPLETED
Trial details
- NCT number
- NCT05532124
- Sponsor
- Green Cross Wellbeing
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-01
- Primary completion
- 2023-05-25
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.